KR100716389B1 - N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}벤즈아미딘 2메탄술폰산염 - Google Patents
N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}벤즈아미딘 2메탄술폰산염 Download PDFInfo
- Publication number
- KR100716389B1 KR100716389B1 KR1020050111543A KR20050111543A KR100716389B1 KR 100716389 B1 KR100716389 B1 KR 100716389B1 KR 1020050111543 A KR1020050111543 A KR 1020050111543A KR 20050111543 A KR20050111543 A KR 20050111543A KR 100716389 B1 KR100716389 B1 KR 100716389B1
- Authority
- KR
- South Korea
- Prior art keywords
- phenoxy
- isopropyl
- hydroxy
- methyl
- thiazol
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
Abstract
Description
메탄술폰산 함량 | |
이론치 | 29.76 % |
측정치 | 30.02 % |
메탄술폰산 함량 | |
이론치 | 17.48 % |
측정치 | 17.68 % |
용매 | free base | 사용염 | |
1 메탄술폰산염 | 2 메탄술폰산염 | ||
증류수 | 3.48 | 414.34 | 3,535.33 |
pH 1.2 | 950.87 | 1,092.98 | 1,686.71 |
pH 4.0 | - | 0.99 | 3.00 |
함량(%) | |
초기 | 99.85 |
2일 후 | 99.86 |
1주일 후 | 99.87 |
2주일 후 | 99.86 |
free base | 사용염 | ||
1 메탄술폰산염 | 2 메탄술폰산염 | ||
용량 | 50mg/kg | 50mg/kg | 50mg/kg |
마리수 | 4 | 4 | 4 |
혈중최고농도 (㎍/mL) | 1.09±0.17 | 1.40±0.11 | 1.67±0.32* |
혈중농도시간곡선하면적(㎍/mL) | 5.31±0.49 | 7.01±0.60* | 10.28±0.80*,# |
Claims (9)
- N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}벤즈아미딘 2 메탄술폰산염.
- 불활성 용매 중에서 N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}벤즈아미딘과 메탄술폰산염을 반응시키는 단계를 포함하는, N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}벤즈아미딘 2 메탄술폰산염의 제조방법.
- N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}벤즈아미딘 2 메탄술폰산염 및 약제학적으로 허용가능한 담체를 포함하는 골다공증 예방 및 치료용 약제학적 조성물.
- N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}벤즈아미딘 2 메탄술폰산염 및 약제학적으로 허용가능한 담체를 포함하는 골절 치료용 약제학적 조성물.
- N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}벤즈아미딘 2 메탄술폰산염 및 약제학적으로 허용가능한 담체를 포함하는 알러지성 염증 질환의 예방 및 치료용 약제학적 조성물.
- N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}벤즈아미딘 2 메탄술폰산염과 함께, (a) 탄산 알칼리금속염, 탄산수소 알칼리금속염 및 탄산 알칼리토금속염으로 이루어진 군으로부터 선택된 탄산염; (b) 카르복시메틸스타치나트륨, 카르멜로오스나트륨, 카르멜로오스칼슘 및 크로스카르멜로오스나트륨으로 이루어진 군으로부터 선택된 붕해제; 또는 (a) 및 (b)를 모두 포함하는, 골다공증, 골절 또는 알러지성 염증 질환의 예방 및 치료용 경구 제형물.
- 제6항에 있어서, 무기 부형제를 추가로 포함하는 경구 제형물.
- 제7항에 있어서, 무기 부형제가 인산수소칼슘, 인산칼슘, 중질 산화마그네슘, 침강탄산칼슘, 탄산마그네슘 또는 이들의 혼합물인 경구 제형물.
- 제6항 내지 제8항 중 어느 하나의 항에 있어서, 탄산염이 탄산수소나트륨 또는 탄산칼슘이고, 붕해제가 카르복시메틸스타치나트륨 또는 크로스카르멜로오스나트륨인 경구 제형물.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20040096390 | 2004-11-23 | ||
KR1020040096390 | 2004-11-23 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20060057511A KR20060057511A (ko) | 2006-05-26 |
KR100716389B1 true KR100716389B1 (ko) | 2007-05-11 |
Family
ID=36498212
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050111543A KR100716389B1 (ko) | 2004-11-23 | 2005-11-22 | N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}벤즈아미딘 2메탄술폰산염 |
KR1020050111779A KR101047042B1 (ko) | 2004-11-23 | 2005-11-22 | 생체이용율을 향상시킨 경구용 제제 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020050111779A KR101047042B1 (ko) | 2004-11-23 | 2005-11-22 | 생체이용율을 향상시킨 경구용 제제 |
Country Status (19)
Country | Link |
---|---|
US (2) | US20070254930A1 (ko) |
EP (2) | EP1814593A4 (ko) |
JP (2) | JP4774053B2 (ko) |
KR (2) | KR100716389B1 (ko) |
CN (3) | CN100574756C (ko) |
AT (1) | ATE445397T1 (ko) |
AU (2) | AU2005307994B2 (ko) |
BR (2) | BRPI0517396A (ko) |
CA (2) | CA2552766C (ko) |
DE (1) | DE602005017118D1 (ko) |
DK (1) | DK1701722T3 (ko) |
ES (1) | ES2333739T3 (ko) |
HK (1) | HK1094530A1 (ko) |
IL (2) | IL180985A (ko) |
NZ (1) | NZ555725A (ko) |
PT (1) | PT1701722E (ko) |
RU (1) | RU2361867C2 (ko) |
WO (2) | WO2006057507A1 (ko) |
ZA (2) | ZA200700485B (ko) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1773333A4 (en) * | 2004-07-05 | 2010-04-21 | Dong Wha Pharm Co Ltd | COMPOSITION FOR THE PREVENTION AND TREATMENT OF ALLERGIC INFLAMMATORY DISEASES |
KR20060017929A (ko) * | 2004-08-04 | 2006-02-28 | 동화약품공업주식회사 | 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물 |
CN100574756C (zh) * | 2004-11-23 | 2009-12-30 | 同和药品(株) | 具有改善生物利用度的口服制剂 |
ATE494282T1 (de) * | 2007-04-19 | 2011-01-15 | Dong Wha Pharm Co Ltd | 2-ethansulfonsäuresalz aus n- hydroxy-4-ä5-ä4-(5- isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxyüpentoxyü benzamidin, verfahren zu seiner herstellung und pharmazeutische zusammensetzung damit |
JP5656258B2 (ja) * | 2011-03-09 | 2015-01-21 | 塩野義製薬株式会社 | ガランタミンを含有する口腔内崩壊錠剤 |
US9945862B2 (en) | 2011-06-03 | 2018-04-17 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
JP6292744B2 (ja) * | 2012-09-19 | 2018-03-14 | 富士カプセル株式会社 | 医薬品組成物 |
EP2952196A4 (en) * | 2013-01-31 | 2016-08-03 | Sawai Seiyaku Kk | MULTILAYER TABLET CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE |
EP4089076A1 (en) | 2014-08-28 | 2022-11-16 | Eisai R&D Management Co., Ltd. | High-purity quinoline derivative and method for manufacturing same |
CA2976325C (en) | 2015-02-25 | 2023-07-04 | Eisai R&D Management Co., Ltd. | Method for suppressing bitterness of quinoline derivative |
WO2016140717A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharp & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
MX2017013896A (es) | 2015-04-28 | 2018-03-15 | Astellas Pharma Inc | Composicion farmaceutica para administracion oral. |
KR20180018695A (ko) | 2015-06-16 | 2018-02-21 | 가부시키가이샤 프리즘 파마 | 항암제 |
BR112020003380A2 (pt) * | 2017-08-18 | 2020-08-25 | Abbvie Inc. | formulações farmacêuticas para o tratamento de endometriose, miomas uterinos, síndrome do ovário policístico ou adenomiose |
KR102276547B1 (ko) * | 2020-09-04 | 2021-07-13 | 주식회사유한양행 | 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030008654A (ko) * | 2001-07-19 | 2003-01-29 | 동화약품공업주식회사 | 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8518301D0 (en) * | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
US5091191A (en) * | 1988-02-03 | 1992-02-25 | Yoshitomi Pharmaceutical Industries, Ltd. | Pharmaceutical composition with improved dissolution property |
PA8441701A1 (es) * | 1996-11-26 | 2000-05-24 | Pfizer | Sales dimesilato de los ligandos del neuropeptido y |
UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
KR100642953B1 (ko) * | 1999-10-28 | 2006-11-10 | 상꾜 가부시키가이샤 | 벤즈아미딘 유도체 |
KR100789567B1 (ko) * | 2001-11-06 | 2007-12-28 | 동화약품공업주식회사 | 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도 |
ATE541575T1 (de) * | 2002-03-06 | 2012-02-15 | Effrx Pharmaceuticals Sa | Brausetabletten, enthaltend alendronat |
EP1495005A1 (en) * | 2002-04-12 | 2005-01-12 | Pfizer Japan Inc. | Pyrazole compounds as anti-inflammatory and analgesic agents |
US7157100B2 (en) * | 2002-06-04 | 2007-01-02 | J.B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical composition for controlled drug delivery system |
JP4669391B2 (ja) * | 2003-03-18 | 2011-04-13 | 興和株式会社 | 制酸剤組成物 |
CN100574756C (zh) * | 2004-11-23 | 2009-12-30 | 同和药品(株) | 具有改善生物利用度的口服制剂 |
-
2005
- 2005-11-22 CN CN200580038889A patent/CN100574756C/zh not_active Expired - Fee Related
- 2005-11-22 EP EP05821036A patent/EP1814593A4/en not_active Withdrawn
- 2005-11-22 CA CA2552766A patent/CA2552766C/en active Active
- 2005-11-22 AT AT05817697T patent/ATE445397T1/de active
- 2005-11-22 CN CN2009101666678A patent/CN101693029B/zh not_active Expired - Fee Related
- 2005-11-22 KR KR1020050111543A patent/KR100716389B1/ko active IP Right Review Request
- 2005-11-22 RU RU2007123614/04A patent/RU2361867C2/ru active
- 2005-11-22 BR BRPI0517396-5A patent/BRPI0517396A/pt not_active IP Right Cessation
- 2005-11-22 ES ES05817697T patent/ES2333739T3/es active Active
- 2005-11-22 AU AU2005307994A patent/AU2005307994B2/en not_active Ceased
- 2005-11-22 AU AU2005300239A patent/AU2005300239B2/en active Active
- 2005-11-22 US US11/577,469 patent/US20070254930A1/en not_active Abandoned
- 2005-11-22 JP JP2007523495A patent/JP4774053B2/ja active Active
- 2005-11-22 CN CN2005800017444A patent/CN1905871B/zh active Active
- 2005-11-22 KR KR1020050111779A patent/KR101047042B1/ko not_active IP Right Cessation
- 2005-11-22 DK DK05817697T patent/DK1701722T3/da active
- 2005-11-22 US US10/584,984 patent/US20090176846A1/en not_active Abandoned
- 2005-11-22 PT PT05817697T patent/PT1701722E/pt unknown
- 2005-11-22 JP JP2007542909A patent/JP4773456B2/ja not_active Expired - Fee Related
- 2005-11-22 WO PCT/KR2005/003950 patent/WO2006057507A1/en active Application Filing
- 2005-11-22 EP EP05817697A patent/EP1701722B1/en active Active
- 2005-11-22 NZ NZ555725A patent/NZ555725A/en unknown
- 2005-11-22 WO PCT/KR2005/003934 patent/WO2006057501A1/en active Application Filing
- 2005-11-22 DE DE602005017118T patent/DE602005017118D1/de active Active
- 2005-11-22 BR BRPI0514386A patent/BRPI0514386B8/pt active IP Right Grant
- 2005-11-22 CA CA2585003A patent/CA2585003C/en not_active Expired - Fee Related
-
2007
- 2007-01-17 ZA ZA200700485A patent/ZA200700485B/en unknown
- 2007-01-25 IL IL180985A patent/IL180985A/en active IP Right Grant
- 2007-02-08 HK HK07101468.4A patent/HK1094530A1/xx unknown
- 2007-04-18 IL IL182647A patent/IL182647A/en not_active IP Right Cessation
- 2007-05-24 ZA ZA200704236A patent/ZA200704236B/xx unknown
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20030008654A (ko) * | 2001-07-19 | 2003-01-29 | 동화약품공업주식회사 | 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100716389B1 (ko) | N-히드록시-4-{5-[4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시]펜톡시}벤즈아미딘 2메탄술폰산염 | |
ES2397307T3 (es) | Composición de solifenacina o una sal de la misma para su uso en una formulación solida | |
AU2016253911B2 (en) | Carboxylic acid URAT1 inhibitor containing diarylmethane structure, preparation method and use thereof | |
CN112851666B (zh) | 阿哌沙班与槲皮素共晶物及制备方法和其组合物与用途 | |
TWI415613B (zh) | Anti-cancer agent resistance to overcome the agent | |
KR20210102887A (ko) | 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제 | |
CN110041325B (zh) | 盐酸小檗碱与布洛芬共晶物及制备方法和其组合物与用途 | |
WO2006073779A1 (en) | Novel omeprazole forms and related methods | |
KR101006254B1 (ko) | N-히드록시-4-{5-〔4-(5-이소프로필-2-메틸-1,3-티아졸-4-일)페녹시〕펜톡시}벤즈아미딘 2 에탄술폰산염, 이의제조방법 및 이를 포함하는 약학 조성물 | |
WO2001058489A1 (fr) | Agents prophylactiques/therapeutiques contre le stress postoperatoire | |
CZ20013759A3 (cs) | Nový léčivý přípravek | |
CZ20013758A3 (cs) | Nový léčivý přípravek | |
WO2005021543A1 (en) | Phosphoric acid salt of 5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2, 4-thiazolidinedione | |
KR20080003604A (ko) | 피롤로피리미디논 유도체의 헤미타르트레이트 염 및 이의제조방법 | |
WO2005023790A1 (en) | (s)-(+)-2-ethoxy-4-{[3-methyl-1-(2-piperidin-1-yl-phenyl)-butylcarbamoyl]-methyl}-benzoic acid sodium salt | |
PT100976A (pt) | Composicao farmaceutica a base de inibidores da renina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
J202 | Request for trial for correction [limitation] | ||
J301 | Trial decision |
Free format text: TRIAL DECISION FOR CORRECTION REQUESTED 20101203 Effective date: 20101231 |
|
FPAY | Annual fee payment |
Payment date: 20130115 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20140212 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20150115 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20160111 Year of fee payment: 10 |
|
FPAY | Annual fee payment |
Payment date: 20170120 Year of fee payment: 11 |
|
FPAY | Annual fee payment |
Payment date: 20171228 Year of fee payment: 12 |
|
FPAY | Annual fee payment |
Payment date: 20181221 Year of fee payment: 13 |
|
FPAY | Annual fee payment |
Payment date: 20191219 Year of fee payment: 14 |